taking I We for thank morning. this the providing update forward of you, everyone, to quarter. you, appreciate and joining last an you Thank time. the us look Mike, you
release this in out mentioned we press we first of year. the half very for strongly really the closed yesterday, As
the just let's quarter start So second highlights. with some of
just over volume X,XXX to side, XX% a quarter-on-quarter. have EsoGuard we're execution grown That's excited commercial tests. to test From
little quarterly through detail this annual XXX% about commercial centers continuing various another satellite a the seller growth on more our bit our of growth testing in the and events. our increased high-volume talk activities were So later and an productivity drivers but of increased double-digit test and execution, basis. We'll aspects
all some revenue strategic We that important That A on also I and that and in in July. of certainly Again, the and May well was immediate that claims had us is most that last recent more cycle that very will really in and the infrastructure weeks very quarter accomplishments management provider. of an was took month positive upgraded detail detail. a review both of important talk completed. for during our our and quarters. process we coming milestone in bode the I'll now some about payments, which processing we June, and in impact some saw And process Dennis
between the we've milestone its be The will analyzed. And are and critical over be manuscript posted talking later surpassed XXX engagement and will month. two studies very utility results be are studies. reached first actually it submitted quarter patients -- and each with payers prospective clinical this our first about that They'll for the enrollment at those been being
a I'll headline XXX% the study see consortium. were of unprecedented the of of but bit We BETRNet the some the XX% over pre-cancer, highlight again, also little excited to we're cancer EsoGuard detection and results from NCI-funded for unprecedented. later, of results these
our contract, as first direct executed the employee just time, company we employer recently where, completed a first an for EsoGuard will be And and offering benefit.
detail. those about talk a So more in again, bit we'll
test diagnostic new available test commercially of and test biomarker available you a the The detection key two products: testing, of Esophageal is cell through has tool the EsoCheck. just only introduce to A to the which widespread as that's molecular EsoGuard device. only DNA the ours and They alternative and Lucid form capable first those esophageal the endoscopy. few early EsoCheck who EsoGuard slides are or collection non-endoscopic cancer story. pre-cancer. one associations deaths prevent to major an of as commercially to supported gastroenterology serving acceptable have that's Both of EsoGuard
highly -- any actually unlike the to have gruesome. that for detect I through where Stage esophageal for the an to opportunity The an one esophageal like a slide. is is is importantly, in other cancer. recommended Less a those all to screening we which not won't but go the highlight death preventable. is middle the by rate I cancer pre-cancer, on only is for pretty and our impact for most than Stage Next happening. XX%, just way statistics enemy over considerable mortality I The is cancer one lethal it's cancer purposes, considered Therefore, here, diagnosis endoscopy. are is the X% that and, they're that's is undergoing the of cure. guidelines
the I patient detection I saving on lives. thought about the Hill a I our a you touch did how a driven really team Steve. story give every And lives this to that this sense will and I'd patients' patient this on to share is today, an day here save I'd tell is Capitol to the are work day, during a lives, Because and on to the by of impact opportunity as end month, at the thought does testimony patients who such last have story. call of using as bit more but early
considered. And endoscopy no educational allergist's over as lives smoker, was boxes in he he agent, had the XX-year-old he be heartburn. He Northwest. saying, an should and Freddie your some And had follow-ups a years [indiscernible] "Check XX the of former you had Freddie therefore, on realized of ago, had heartburn. such who white a Long-time criteria The the over risk check he to Prilosec. one our right as Steve through Pacific met [indiscernible]. is but saw it PPI He posters He who and then. was was former food." And waiting sufferer was factors. chronic medication, Freddie, room, in since the smoker on male, his of and poster
He that collection the was to allergist test, office. they cell physician at order performed the procedure The and physician did. asked
this one of where So are the doing EsoCheck is those offices came And that positive. themselves. the procedure back personnel test
asked that and showed endoscopy, to a patch, a follow-up a recommended patients long positive lethal had This which had late-stage endoscopy up a go, only was these X-inch is picked he his developing he EsoGuard it highly segment the the high-grade pre-cancer, his was are health and poster so-called was quite dysplasia. cancer, before He and is last it about as the thought And test. because who have about all undergo. -- step read showed things for and the assertive a test this as health,
undergone say would we that that cancer pre-cancer the had not the have progressed. that would likely he years, that coming if test, think have time his his can some I unequivocally progressed in cancer. dysplasia The -- at it's very to
what and underwent procedures out was recommended month. with referred he he that series and undergo, that curative is a state which using are -- ablation to So are endoscopy, of done diagnosis completed of underwent was patients last this
test. life than any The when that my and is I the prevention by really, getting a the a damn caught said, it can't I think I'm easier flyer I quote direct had the more seeing "I caught better say I think lucky I own And saved cure. it.
says really that So it all."
patient patients is From of heartburn the who recommended know a and for population patients. This guidelines. XX view, the number are really is who opportunity million point group pre-cancer core those chronic here by commercial of testing of vast. We the have
Some guidelines that. number have of actually beyond the that expanded
And said as several that set we price does calls, to has be payers. and our prior Medicare grow engagement as price appear of a that holding activity our with on increase we've $X,XXX.
we market are margin a high are that's a at we close we over -- where very very, of are very gross today. So that have large volumes And XX% to opportunity.
this quarter-on-quarter can just view? about testing mentioned, how And had a see a of nice, As from quarters. X,XXX grew period point tests. you going past commercial So growth in do for very time, double-digit back we we've to XX% of I quarter steady EsoGuard X volume did
fair note get a to want because we did asked this I amount.
we're test with that regard manufacturing? capacity we we volume, to approaching And are our are laboratory or not. As growing
our is to capacity able manufacturing -- to up that. sufficient keep XX,XXX have we have and perform We laboratory quarter, over tests with per
specialists test There being about are is referred trends performed? referring the and and are the a evolving the stabilized are -- collection patients with and physicians, still some regard who being who to We've test patients XX% variety being this primary of are by by portion care rest cell institutions. of referred to XX% the of is for where
performed number of are the the changing, of collection -- that is by practitioners, cell we as is an that Lucid procedure those and performed show thing to satellite our are number continue increasing in increase being test the nurse center. at being where patients being One
his the hold XX physician about So and are of branch physician we but That's centers all day anchor. allergists. test nurse physician time have to practitioners Steve and cell the the procedure there. country, are centers across That's we test And are in have their the collection out Lucid who did there -- cities have doing by own undergoing they spend their satellite we the X/X to to centers sessions travel with still physical but they with where we the as the offices patients home, a office. are based test their in able
the volume So execution. at really how the great growing. is views on Really proud test commercial
that clinical sales we team, nurse the actually of shown noted productivity year, both the increased since sales of consists you sellers the are team, of well as representatives, beginning the that -- year. year beginning And If in the froze the earlier as which practitioners, the at our the have field -- team.
of are this So growth. same number sellers generating
team. the clinical between coordination improved sales and There's
do our Some high-volume practitioners a park a of which system. nurse rate the demand that's to sufficient hit of And driven out rates. are testing technical continue success put who the with collection on XX% and D&A the it by folks procedure high events, EsoCheck very these
test mentioned, Lucid more SLTC a flexibility, striving. home much center model, the engagement, patients that reach the front it days satellite physical the it location, us can more is helps from with there much nurse the or geographic and efficiency the base As when because keeps the It gives broader model physician testing nurses we I are center. practitioners multiple and And assure there are scheduled. and of
that that and see we to case be quarter-on-quarter, continue continues so And to positive impact. the
order the team practices parking required We launched mobile do tests in requirements a where that their a tested. is that where that for We state test get regulatory satellite on to lot for the to time. to are And model. the want us in us patients have order unit demand the the where our first Florida bring ask to their physician have walk-ins, demand patients or Florida.
And it's Florida. Freddie to that's we and message that also the bandwidth the something asked about states, that around our We've been and of have expanding marketing and that tool other moving we're in driving carving marketing continuing states, volume to mandatory considering. so But here. And test drive don't doing. continue we're a other for forward have in mobile we're unit, that now, as we'll to this to push have need
foot detection check of in We year. activities continue. the in This your pre-cancer this announced growth first the quarter With started those event. firefighters, the
They We -- continue do people volume. to our continue of larger. again, some these, smaller, this. significant importantly, a to many about represent inquire But do some
physicians growth not and business the care primary is in growth cannibalizing That traditional the other specialists. referral from
part It's access, at be. philosophy opportunity of might patient to So additive. of it's wherever increase it access our every looking
strong -- it center our We've and There increase also, Again, do exposure. about have departments police us mostly been resources had CYFT media expands hearing examples the to our activity and led we're this, moved had in a hospital firefighter after that expand major although event where geographic region we've continuing get firefighters, reach, reach. from many including we've divert there their a contacted there. one and us event physicians, to and
operational the All and effort a that's and been we substantially. program and get these is some to organized have complicated. dedicated this time It efficiency installed takes of enhanced manager
a this test. part patients effort So to significant get access this of will remain to our
had more These on more are focus difficult. also we've obviously, a time. be and And little an large But health the They increased take payoff systems more lead IDNs. There's large. can time.
those technology even play, translate through system so forth large If into made get -- more in and a early account. regional we've within a activity health and working getting or strategic national can progress in clearance successes committees to that you systematic
So we in locking we've large have quarters. of we're that a and engaged pipeline looking accounts those coming with, the down towards
about talk coverage. and payment claims Dennis some wanted in to of that about the topics aspects a comments this. These strategic few a are of highlight detail. So will just I few
to are things us to on that you that the provide at If for that I our the go there we collect right, ability the tests that to longer-term graphic remind ultimately, payment towards you just to look coverage growth. want drive and perform, contracts get revenue multiple
claims They history. a include generating
paid tests your having about get and management being through revenue by won't being commercial on on a You until ordered robust of data, submitted and bit passing appeals It's dependent more later. cycle claims process which forth. the see and generating I'll clinical utility payers they detail process, dependent even a talk in so
then and their there's demonstrated But important policy of our discipline and very, of clinical driver. very of a it's around, see is We'd The whole our to majority access questions engagement engaging part that payers. all utility. like vast around time, market a you critical have medical And with primary that. are another
substantial on completed. of the been most we've cycle last is our So one, on all to process infrastructure. happen and was call, them. has the now The for management previewed near progress our made this about made that we revenue term, in upgrade important We
fact, engaged is the years diagnostic significantly a RCM. multibillion-dollar in the Diagnostics one has We a that of was provider largest in larger we RCM had. companies. capacity many company leader for for the than was the This molecular -- market And
-- -- positive quarter. May Dennis we The a of impact adjudication had facilitate beginning numbers the was obviously July through That bit payments as those were all on -- that. of -- These of But in as -- success in positive not allowed receipts a in of a us. claim to quarter, in to go the about really all on a Again, claims That will June impact from including price. period near-term immediate average was impact we submissions prior well net allowed average fronts, the short-term and from to order the the this the as some XX. preview. transition, of sale X-week striking the for paused
The element can processes. to prior authorization commercial the be -- quite very payers with another key is These appeals important. the and being successful
it we're very front ago, necessity our much to them process in X of weeks decisions actually medical more through robust have go to their directors appeals aspects partner other engage You on with regard. coverage in to get is medical and to new of That get with than was that that. and happy
access again, mentioned of that I drivers and are our I'll utility. policy still team. As clinical coverage payment we've reiterate Also growth the medical revenue market claims history and and revamped
in a have that and we're with of lead -- forward yesterday, strategically engagements initiatives We and us whole started focused to. to payers a variety will looking new that leader this role she
entities brief This touched EsoGuard directly effort A for contracting here other strategic on we've for to comment initiative. before. go employers, self-insured these our unions, Again, services. contract us this is to on and directly direct an seek to
fruit. more is process that them, With
contract it's with offered more first employer in benefit is test employee our that Texas-based now the is automotive the as at this But information on program that be coming our -- providing a We'll with EsoGuard We weeks. an first satellite group. XX being have time locations automotive group. through
So very forward milestone, we've that we're achieved very, more. happy look and that we to
pushing we're can these, to periods the someone enrollment director timing in can like, and so And role. we cycle forth, be hiring aggressively. The forward strategic longer they are and with a this but actually open on accounts be quite
clinical Okay. I've already mentioned utility.
coverage. with has means -- efforts an order test impact it in to our and Clinical Let to network that is payers this with commercial decision-making. drive really medical our the utility our heart at -- mention on because is of payers me again, engage and
wants is test that result is to -- if endoscopy a like generate is likely a -- to patient surveillance other and expensive know payer if to not What an than some diagnosis follow-up the our positive, follow-up either more get a another plan, a a to They that, know want also or endoscopy. test that ablation negative, will won't test test, that confirm that treatment. in confirm the to follow-up that that demonstrate
fork straightforward is that really the looking type actually diagnostic and that I algorithm The of for the complicated road So for tests. very the prospective other test. mentioned. data. payers actually it's just our straightforward more quite key than some is in It's data are It's
And own our through so patients studies, as of centers. is have Both we've discussed two before, study, our a test LUCIDregistry, listed we study dominated by the prospective which multicenter CLUE is the those which are prospective. coming and
We both. the mid-summer exceeded that had target we've enrollments for
us patients data, doing That forward preprint for end for over the and We and analyze review submit sufficient on XXX it have month, -- that. peer this of a server submit for between we to to a the of the total look is two. it posted by
will that That coverage and process contracting. necessity discussions, payers be is negotiations by the demonstrations able highlight which in-network to we data and for of for engaging medical in
So we're We're to of to very have that future. our the be going that to in going present data, ready and to set payers first process is go. able near to
the the have the first testing Firefighters. also retrospective Antonio We very That's from high-volume event retrospective. analysis San and
the it's as it's percentage review decision And that powerful, appropriate on the the useful. outcome data it described of submitted, The but medical previously. and That of journal. high with was peer very, test the was and in test, concordance excellent. the manuscript not undergoing as being is the made gastroenterology very I for So
structured very recruit these their where in piece central that patients to are you be kinds and type but as closing be what of discussions That in registry. of studies recruit That do supplemental they we're useful virtual used in -- the give would data, vignette of as that forward data will a decision with Another a will near payers you from the the future is to ongoing well. test to fashion. physicians CLUE recruitment, and commonly study is the looking nice study a patient
utility. published validity I originally be in that continue won't studies. of talking to was just science clinical That's as our the performance years the document depth clinical in Those translational are about much studies medicine ago. test
study, five enrolled patients previously a BETRNet -- that data study pausing. That which analyzed. XXX BE So there before the we've study, VA is The BE-X study in we study, about studies, announced. are the being is which
to likely Reserve from that has CaseWestern And we'll details of The case BEX NCI. the non-DER I control results and those first except a roll study is next talk of also continuing half the readout in the another of year. on that's into, study we're enrollment. study a its brief the in ongoing highlight a BETRNet have for won't
going that more brief coming in just on providing weeks a give of to We as I'm information that. summary well. on plan the
So consortium of -- BETRNet esophageal academic centers. medical the is really BETRNet pre-cancer. in and leading a the major disease esophegeal study figures They're
This preservative. names EsoGuard first It of generated Mayo see the tested on can a that previous UHC The our samples. Clinic, real-world there, in right with research a study the our Cleveland all Clinic used temperature use and the more standard was endoscopy the and You versus case room in test. is frozen Western, of Hopkins, a control study participated of study study Case WashiU, was study.
to true Science a in very that wasn't in was Medicine of milestone for XXX% that the Translational study So the underwent original EsoCheck And achieve. again, patients paper. collection. cell important the us
the numbers XX% the but patients, on the at access started there. the see end will evaluable. and XXX full that, rate. patients breakdown they success XXX highlight won't rate XX% can with were I go that the technical I had overall about of numbers the two You that through
the this a have practitioners. but our for the nurse doing have the these next results, bit were lower rates that I'll that did were same note occurred centers were training that our These centers, than own predominantly success we centers in that like. academic the rigorous which excellent, to earlier are overall on experience fact and in would not slide, we despite that Just for competency show now
substantially success So better rate I is better than test center here, in-house about technical XX%, Lucid and XX%, substantially than highlighted which the that our XX% again, XX%. overall is our is earlier success
excellent of likely overall So to benchmark are we the for the better here that believe current success are [indiscernible]. that the results reported given be
showing slide headline some I'll last which we early here some comparisons. cancer These this results one comparable So And -- as caveat are other into results from not the before test. detection detail the go I targets. has head-to-head that are
cancer used What I'd were widely being metrics to show approved, that other is be to them getting the led metrics -- being used that like FDA and approved, case highly or certainly expected successful to detection the coverage successful. here early what performance test, -- or were successful [corridor] being will that
XXX% the EsoGuard were in those studies use said, there, screening results of obviously, case-control The you can that which is, of in intended picked see population. quite does study. a regard. their as Many Cologuard cancers, That are well EsoGuard up
liquid quite blood a The that's Garden, XX%. are one, getting biopsy test which Stage at XX%. the those numbers is is lot in poor And attention of at
cancers. All the Stage were I by that EsoGuard were cancers XXX% detected of
for greater all side. study. about The a clip. That test unprecedented the blood XX% most cancer for in really diagnostic Cologuard better moment at rate molecular recent is pre-cancer test. The detection a our picks The at picture a hardly number bit at advanced up on for XX% XX% is a for pre-cancer is garden.
XX% is by critical So this pre-cancers, unprecedented the number, XX% for is then quite this overall and and number, this XX% again, which the dominated really, -- cancer.
for cure. cancer, Picking I mentioned, up as Stage opportunity a a colon an has X
-- to we're detection and have XX% that have gratified no the have in choice that, but is the number to rate We we cancer range, holding.
that's check. we gut That's it be. where a up an right, additional all pre-cancer on won't numbers for of number the negative That's through predictive cancer go to but based And setting. to three it's in a prevalence needs at the what the trying that's them, XX%. I be is some expect or pick the value -- estimated on There's test to good
the rate, that overall including is not Again, than miss for comparable, what X% better pre-cancers. if to want benchmark miss so any very don't the is X% others. You --
baton over Dennis, I the So our with will of financial that, will give some summary to who results. hand
